The Native Antigen Company has rapidly become one of the world’s leading suppliers of infectious disease reagents. Our portfolio of reagents continues to expand rapidly, and we are widely acknowledged to be a primary source of reagents and kits for the study of emerging diseases. In July of 2020, The Native Antigen Company was acquired by The LGC Group, a global leader in the life sciences sector, and is now part of the LGC Clinical Diagnostics business unit.
